FDA Nanotechnology Task Force Takes Positive Step Forward

Agency Needs More Resources, Continued Transparency to Ensure Confidence in Safety

STATEMENT BY MICHAEL R. TAYLOR
Former FDA Deputy Commissioner for Policy (1991-94)

Today’s report from the Food and Drug Administration (FDA) Nanotechnology Task Force is an important and positive step forward in the agency’s effort to tackle the new scientific and regulatory challenges posed by nanotechnology.

The Task Force is clear and candid in acknowledging the pervasive potential of nanotechnology to affect virtually every product category FDA regulates—from pharmaceuticals and devices to cosmetics and food supplements—and in calling for a wide range of FDA actions to prepare for and execute its oversight role. While available evidence does not suggest that all materials with nanoscale dimensions will be hazardous, the Task Force correctly concludes that the agency needs new safety assessment tools, greater nano-specific staff expertise and more risk research to assess the likelihood of long-term health effects from exposure to specific nanoscale materials.

The report also recognizes the need to gather more information from industry, especially to answer safety-related questions, and to provide companies with clear guidance so there can be reasonable and safe pathways to market for the many potential applications of nanotechnology under FDA’s jurisdiction.

Equally important, the report signals FDA’s commitment to a transparent public process for developing its regulatory policies. Public participation will be key both to developing good policies and winning public confidence in the agency’s oversight of nanotechnology, and I applaud the Task Force and FDA for taking this approach.

Finally, the extensive nanotechnology “to do” list outlined in the report should remind Congress, as it considers FDA’s 2008 budget, that it needs to fix the problem of FDA’s chronic underfunding. The agency urgently needs more resources to do what needs to be done on nanotechnology—and do it urgently—along with the many other challenges the agency faces.

#  #  #
Michael R. Taylor is a research professor at the George Washington University School of Public Health and Health Services. In addition to serving as deputy commission for policy, he was an FDA staff lawyer and executive assistant to the FDA commissioner from 1976 to 1981. He is the author of a comprehensive report on FDA’s “nano-readiness” commissioned by the Project on Emerging Nanotechnologies, Regulating the Products of Nanotechnology: Does FDA Have the Tools It Needs? (October 2006); available at: www.nanotechproject.org

The Project on Emerging Nanotechnologies is an initiative launched by the Woodrow Wilson Center and The Pew Charitable Trusts in 2005. It is dedicated to helping business, government and the public anticipate and manage possible health and environmental implications of nanotechnology.